

Public Health Genomics and Precision Health Knowledge Base (v6.9)

PHGKB
About
MyPHGKB
Specialized PHGKB
Genomics (A-Z)
Office of Genomics and Precision Public Health
My Family Health Portrait
State Public Health Genomics Programs Map
Genomics & Health Impact Weekly Scan (Current Edition)
Advanced Molecular Detection Weekly Clips (Current Edition)
Non-Genomics Precision Health Update
CDC-authored Publications Update
COVID-19 Genomics Precision Health Update
All Databases
DataSet Download Center
Release Note
Contact Us

Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Recommend Tweet Share

Published on 12/17/2020

COVID-19 Genomics and Precision Public Health Weekly Update Content

- [Pathogen and Human Genomics Studies](#)
- [Non-Genomics Precision Health Studies](#)
- [News, Reviews and Commentaries](#)

Pathogen and Human Genomics Studies

- [Molecular epidemiology of SARS-CoV-2 clusters caused by asymptomatic cases in Anhui Province, China.](#)
 Yuan Yuan et al. BMC infectious diseases 2020 Dec (1) 930
 We conducted an epidemiological investigation of two clusters caused by asymptomatic infections sequenced the spike gene of viruses isolated from 12 patients. All cases of the two clusters we investigated had clear contact histories, both from Wuhan, Hubei province. The viruses isolated from two outbreaks in Anhui were found to show a genetically close link to the virus from Wuhan. In addition, new single nucleotide variations were discovered in the spike gene.
- [Assessment of an Online Tool to Simulate the Effect of Pooled Testing for SARS-CoV-2 Detection in Asymptomatic and Symptomatic Populations](#)
 CR Polage et al. JAMA Network Open, December 10, 2020
 We created an online tool using actual SARS-CoV-2 virus copy number (VCN) data—the COVID19 Pool Tool—to help policy makers understand how pooled testing compares with single-sample testing in different populations. Pooled testing can extend SARS-CoV-2 test supplies and increase the number of patients tested and cases detected, making it useful for population screening and resource-constrained settings.
- [Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events](#)
 JE Lemieux et al, Science, December 10, 2020
 Analysis of 772 complete genomes from the Boston area epidemic revealed numerous introductions of the virus, a small number of which led to most cases. The data revealed two superspreading events. One, in a skilled nursing facility, led to rapid transmission and significant mortality in this vulnerable population but little broader spread. The second, at an international business conference, produced sustained community transmission and resulted in extensive spread.
- [Genetic mechanisms of critical illness in Covid-19](#)
 E Pairo-Castineira et al, Nature, December 11, 2020
 This is a genome-wide association study(GWAS) in 2244 critically ill Covid-19 patients from 208 UK intensive care units. We identify novel genome-wide significant associations, on chr12q24.13 in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), on chr19p13.2 near the gene encoding tyrosine kinase 2 (TYK2), on chr19p13.3 within the gene encoding dipeptidyl peptidase 9 (DPP9), and on chr21q22.1 in the interferon receptor gene IFNAR2.
- [COVID-19 neutralizing antibodies predict disease severity and survival](#)
 WG Garcia-Beltran et al, Cell, December 15, 2020
 We examined antibody responses in 113 COVID-19 patients and found that severe cases exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-RBD antibody levels. While anti-RBD IgG levels generally correlated with neutralization titer, high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G.
- [Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response.](#)
 Selhorst Philippe et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Dec
 It is currently unclear whether SARS-CoV-2 reinfection will remain a rare event, or whether it will occur more frequently when humoral immunity wanes following primary infection. We report reinfection was confirmed in a young, immunocompetent health care worker as viral genomes derived from the first and second episode belonged to different clades. The reinfection occurred after 185 days, despite an effective humoral immune response following symptomatic primary infection.
- [An Outbreak of Covid-19 on an Aircraft Carrier.](#)
 Kasper Matthew R et al. The New England journal of medicine 2020 Dec (25) 2417-2426
 An outbreak of coronavirus disease 2019 occurred on the U.S.S. Theodore Roosevelt, a nuclear-powered aircraft carrier with a crew of 4779 personnel. We obtained clinical and demographic data for all crew members, including results of testing by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). All crew members were followed up for a minimum of 10 weeks, regardless of test results or the absence of symptoms.

Non-Genomics Precision Health Studies

- [Molecular epidemiology of SARS-CoV-2 clusters caused by asymptomatic cases in Anhui Province, China.](#)
 Yuan Yuan et al. BMC infectious diseases 2020 Dec (1) 930
 We conducted an epidemiological investigation of two clusters caused by asymptomatic infections sequenced the spike gene of viruses isolated from 12 patients. All cases of the two clusters we investigated had clear contact histories, both from Wuhan, Hubei province. The viruses isolated from two outbreaks in Anhui were found to show a genetically close link to the virus from Wuhan. In addition, new single nucleotide variations were discovered in the spike gene.
- [Assessment of an Online Tool to Simulate the Effect of Pooled Testing for SARS-CoV-2 Detection in Asymptomatic and Symptomatic Populations](#)
 CR Polage et al. JAMA Network Open, December 10, 2020
 We created an online tool using actual SARS-CoV-2 virus copy number (VCN) data—the COVID19 Pool Tool—to help policy makers understand how pooled testing compares with single-sample testing in different populations. Pooled testing can extend SARS-CoV-2 test supplies and increase the number of patients tested and cases detected, making it useful for population screening and resource-constrained settings.
- [Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events](#)
 JE Lemieux et al, Science, December 10, 2020
 Analysis of 772 complete genomes from the Boston area epidemic revealed numerous introductions of the virus, a small number of which led to most cases. The data revealed two superspreading events. One, in a skilled nursing facility, led to rapid transmission and significant mortality in this vulnerable population but little broader spread. The second, at an international business conference, produced sustained community transmission and resulted in extensive spread.
- [Genetic mechanisms of critical illness in Covid-19](#)
 E Pairo-Castineira et al, Nature, December 11, 2020
 This is a genome-wide association study(GWAS) in 2244 critically ill Covid-19 patients from 208 UK intensive care units. We identify novel genome-wide significant associations, on chr12q24.13 in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), on chr19p13.2 near the gene encoding tyrosine kinase 2 (TYK2), on chr19p13.3 within the gene encoding dipeptidyl peptidase 9 (DPP9), and on chr21q22.1 in the interferon receptor gene IFNAR2.
- [COVID-19 neutralizing antibodies predict disease severity and survival](#)
 WG Garcia-Beltran et al, Cell, December 15, 2020
 We examined antibody responses in 113 COVID-19 patients and found that severe cases exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-RBD antibody levels. While anti-RBD IgG levels generally correlated with neutralization titer, high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G.
- [Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response.](#)
 Selhorst Philippe et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Dec
 It is currently unclear whether SARS-CoV-2 reinfection will remain a rare event, or whether it will occur more frequently when humoral immunity wanes following primary infection. We report reinfection was confirmed in a young, immunocompetent health care worker as viral genomes derived from the first and second episode belonged to different clades. The reinfection occurred after 185 days, despite an effective humoral immune response following symptomatic primary infection.
- [An Outbreak of Covid-19 on an Aircraft Carrier.](#)
 Kasper Matthew R et al. The New England journal of medicine 2020 Dec (25) 2417-2426
 An outbreak of coronavirus disease 2019 occurred on the U.S.S. Theodore Roosevelt, a nuclear-powered aircraft carrier with a crew of 4779 personnel. We obtained clinical and demographic data for all crew members, including results of testing by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). All crew members were followed up for a minimum of 10 weeks, regardless of test results or the absence of symptoms.

News, Reviews and Commentaries

- [Molecular epidemiology of SARS-CoV-2 clusters caused by asymptomatic cases in Anhui Province, China.](#)
 Yuan Yuan et al. BMC infectious diseases 2020 Dec (1) 930
 We conducted an epidemiological investigation of two clusters caused by asymptomatic infections sequenced the spike gene of viruses isolated from 12 patients. All cases of the two clusters we investigated had clear contact histories, both from Wuhan, Hubei province. The viruses isolated from two outbreaks in Anhui were found to show a genetically close link to the virus from Wuhan. In addition, new single nucleotide variations were discovered in the spike gene.
- [Assessment of an Online Tool to Simulate the Effect of Pooled Testing for SARS-CoV-2 Detection in Asymptomatic and Symptomatic Populations](#)
 CR Polage et al. JAMA Network Open, December 10, 2020
 We created an online tool using actual SARS-CoV-2 virus copy number (VCN) data—the COVID19 Pool Tool—to help policy makers understand how pooled testing compares with single-sample testing in different populations. Pooled testing can extend SARS-CoV-2 test supplies and increase the number of patients tested and cases detected, making it useful for population screening and resource-constrained settings.
- [Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events](#)
 JE Lemieux et al, Science, December 10, 2020
 Analysis of 772 complete genomes from the Boston area epidemic revealed numerous introductions of the virus, a small number of which led to most cases. The data revealed two superspreading events. One, in a skilled nursing facility, led to rapid transmission and significant mortality in this vulnerable population but little broader spread. The second, at an international business conference, produced sustained community transmission and resulted in extensive spread.
- [Genetic mechanisms of critical illness in Covid-19](#)
 E Pairo-Castineira et al, Nature, December 11, 2020
 This is a genome-wide association study(GWAS) in 2244 critically ill Covid-19 patients from 208 UK intensive care units. We identify novel genome-wide significant associations, on chr12q24.13 in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), on chr19p13.2 near the gene encoding tyrosine kinase 2 (TYK2), on chr19p13.3 within the gene encoding dipeptidyl peptidase 9 (DPP9), and on chr21q22.1 in the interferon receptor gene IFNAR2.
- [COVID-19 neutralizing antibodies predict disease severity and survival](#)
 WG Garcia-Beltran et al, Cell, December 15, 2020
 We examined antibody responses in 113 COVID-19 patients and found that severe cases exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-RBD antibody levels. While anti-RBD IgG levels generally correlated with neutralization titer, high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G.
- [Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response.](#)
 Selhorst Philippe et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Dec
 It is currently unclear whether SARS-CoV-2 reinfection will remain a rare event, or whether it will occur more frequently when humoral immunity wanes following primary infection. We report reinfection was confirmed in a young, immunocompetent health care worker as viral genomes derived from the first and second episode belonged to different clades. The reinfection occurred after 185 days, despite an effective humoral immune response following symptomatic primary infection.
- [An Outbreak of Covid-19 on an Aircraft Carrier.](#)
 Kasper Matthew R et al. The New England journal of medicine 2020 Dec (25) 2417-2426
 An outbreak of coronavirus disease 2019 occurred on the U.S.S. Theodore Roosevelt, a nuclear-powered aircraft carrier with a crew of 4779 personnel. We obtained clinical and demographic data for all crew members, including results of testing by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). All crew members were followed up for a minimum of 10 weeks, regardless of test results or the absence of symptoms.

Disclaimer: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.